InfraReDx Receives FDA Clearance for LipiScanâ„¢ IVUS Coronary Imaging System
BURLINGTON, Mass., Sept. 1 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the LipiScanâ„¢ IVUS Coronary Imaging System.
Have Good Effect On Coronary Heart Disease In 9 Chinese Medicine
Astragalus Legume Astragalus root Astragalus or Inner Mongolia, its sweet and slightly warm. Rupi by the lung through. Effectiveness of qi Sun, solid table Deodorant, drainage and wound care, swelling and other diuretic. Professor Zhang pointed out that Astragalus has good cardiac function, coronary distensibility increased myocardial nutritional blood flow, enhance the body's antioxidant capacity, increased SOD activity in blood of patients with coronary heart disease, thus reducing the oxygen to various causes free radicals on myocardial injury. Astragalus may also significantly increase red blood cell sodium pump function of coronary heart disease patients to reduce the concentration of intracellular sodium, on the one hand restore red b...
|
|
 |
 |
|
Women Need Strong Healthy Heart Muscles, Too
With coronary heart disease being the single largest killer of American men and women, one in five deaths in the US is caused by a heart attack, which includes about 250,000 women each year Almost all heart attack survivors die from a second attack or related failure, or suffer a greatly reduced quality of life
How to Prevent Coronary Heart Disease
The changing life style and wrong eating habits have resulted in many dangerous and life threatening health problems One such health problem which many people are facing nowadays is coronary heart disease
FDA Advisory Committee Recommends US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes
WILMINGTON, Del., July 28 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS).
(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )
The Advisory Committee voted as follows:
Questions to the Advisory Committee
Yes
No
Abstain
1.
|
 |
|
